הקליניקה היחידה בישראל עם  CET20 ו THS-3
זימון תורים :054-7831751

References

 

1. Morgan IG, Ohno-Matsui K, Saw SM. Myopia. Lancet. 2012 May ;5;379(9827):1739-48.

 

2. Pan CW, Ramamurthy D, Saw SM. Worldwide prevalence and risk factors for myopia. Ophthalmic Physiol Opt. 2012 Jan;32(1):3-16

 

3. Lin LL, Chen CJ, Hung PT, Ko LS. Nation-wide survey of myopia among

schoolchildren in Taiwan, 1986. Acta Ophthalmol Suppl. 1988;185:29-33.

 

4. Lin LL, Shih YF, Hsiao CK, Chen CJ. Prevalence of myopia in Taiwanese

schoolchildren: 1983 to 2000. Ann Acad Med Singapore. 2004 Jan;33(1):27-33.

 

5. Wu HM, Seet B, Yap EP, Saw SM, Lim TH, Chia KS. Does education explain ethnic differences in myopia prevalence? A population-based study of young adult males in Singapore. Optom Vis Sci. 2001 Apr;78(4):234-9.

 

6. Saw SM, Carkeet A, Chia KS, Stone RA, Tan DT. Component dependent risk factors for ocular parameters in Singapore Chinese children. phthalmology. 2002 Nov;109(11):2065-71.

 

7. Vitale S, Sperduto RD, Ferris FL 3rd. Increased prevalence of myopia in the United States between 1971-1972 and 1999-2004. Arch Ophthalmol. 2009

Dec;127(12):1632-9.

 

8. Wang Q, Klein BE, Klein R, Moss SE. Refractive status in the Beaver Dam Eye Study. Invest Ophthalmol Vis Sci. 1994 Dec;35(13):4344-7

 

9. Saw SM, Katz J, Schein OD, Chew SJ, Chan TK. Epidemiology of myopia. Epidemiol Rev. 1996;18(2):175-87.

 

10. Katz J, Tielsch JM, Sommer A. Prevalence and risk factors for refractive

errors in an adult inner city population. Invest Ophthalmol Vis Sci. 1997

Feb;38(2):334-40.

 

11. Resnikoff S, Pascolini D, Mariotti SP, Pokharel GP. Global magnitude of visual impairment caused by uncorrected refractive errors in 2004. Bull World Health Organ. 2008 Jan;86(1):63-70.

 

12. Saw SM, Gazzard G, Shih-Yen EC, Chua WH. Myopia and associated pathological complications. Ophthalmic Physiol Opt. 2005 Sep;25(5):381-91.

 

13. Worley A, Grimmer-Somers K. Risk factors for glaucoma: what do they really mean? Aust J Prim Health. 2011;17(3):233-9.

 

14. Haug SJ, Bhisitkul RB. Risk factors for retinal detachment following cataract surgery. Curr Opin Ophthalmol. 2012 Jan;23(1):7-11.

 

15. Arevalo JF, Ramirez E, Suarez E, Antzoulatos G, Torres F, Cortez R,

Morales-Stopello J, Ramirez G. Rhegmatogenous retinal detachment after

laser-assisted in situ keratomileusis (LASIK) for the correction of myopia.

Retina. 2000;20(4):338-41.

 

16. Arevalo JF, Azar-Arevalo O. Retinal detachment in myopic eyes after laser in situ keratomileusis. Am J Ophthalmol. 2000 Jun;129(6):825-6.

 

17. Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology. 1984 Dec;91(12):1573-81.

 

18. Jacobi FK, Pusch CM. A decade in search of myopia genes. Front Biosci. 2010

Jan 1;15:359-72.

 

19.Wojciechowski R. Nature and nurture: the complex genetics of myopia and

refractive error. Clin Genet. 2011 Apr;79(4):301-20.

 

20. Mutti DO. Hereditary and environmental contributions to emmetropization and

myopia. Optom Vis Sci. 2010 Apr;87(4):255-9.

 

21. Gwiazda J. Treatment options for myopia. Optom Vis Sci. 2009 Jun;86(6):624-8.

 

22. Walline JJ, Lindsley K, Vedula SS, Cotter SA, Mutti DO, Twelker JD.

Interventions to slow progression of myopia in children. Cochrane Database Syst Rev. 2011 Dec 7;(12):CD004916 .

 

23.Saw SM, Shih-Yen EC, Koh A, Tan D. Interventions to retard myopia progression

in children: an evidence-based update. Ophthalmology. 2002 Mar;109(3):415-21

 

24. Manchikanti L. Evidence-based medicine, systematic reviews, and guidelines in interventional pain management, part I: introduction and general considerations. Pain Physician. 2008 Mar-Apr;11(2):161-86.

 

25 Manchikanti L, Hirsch JA, Smith HS. Evidence-based medicine, systematic

reviews, and guidelines in interventional pain management: Part 2: randomized controlled trials. Pain Physician. 2008 Nov-Dec;11(6):717-73.

 

26.Manchikanti L, Benyamin RM, Helm S, Hirsch JA. Evidence-based medicine,systematic reviews, and guidelines in interventional pain management: part 3:systematic reviews and meta-analyses of randomized trials. Pain Physician. 2009 Jan-Feb;12(1):35-72.

 

27. Walline JJ, Mutti DO, Jones LA, Rah MJ, Nichols KK, Watson R, Zadnik K. The contact lens and myopia progression (CLAMP) study: design and baseline data.Optom Vis Sci. 2001 Apr;78(4):223-33.

 

28. Correction of Myopia Evaluation Trial 2 Study Group for the Pediatric Eye

Disease Investigator Group, Manny RE, Chandler DL, Scheiman MM, Gwiazda JE,Cotter SA, Everett DF, Holmes JM, Hyman LG, Kulp MT, Lyon DW, Marsh-Tootle W,Matta N, Melia BM, Norton TT, Repka MX, Silbert DI, Weissberg EM. Accommodative lag by autorefraction and two dynamic retinoscopy methods. Optom Vis Sci. 2009 Mar;86(3):233-43.

 

29. Chia A, Chua WH, Tan D. Effect of topical atropine on astigmatism. Br JOphthalmol. 2009 Jun;93(6):799-802.

 

30. Wallman J, Winawer J. Homeostasis of eye growth and the question of myopia.Neuron. 2004 Aug 19;43(4):447-68.

 

31. Hung LF, Crawford ML, Smith EL. Spectacle lenses alter eye growth and the refractive status of young monkeys. Nat Med. 1995 Aug;1(8):761-5.

 

32. Adler D, Millodot M. The possible effect of undercorrection on myopic

progression in children. Clin Exp Optom. 2006 Sep;89(5):315-21

 

33. Chung K, Mohidin N, O'Leary DJ. Undercorrection of myopia enhances rather than inhibits myopia progression. Vision Res. 2002 Oct;42(22):2555-9

 

34. Walline JJ, Lindsley K, Vedula SS, Cotter SA, Mutti DO, Twelker JD.

Interventions to slow progression of myopia in children. Cochrane Database Syst Rev. 2011 Dec 7;(12):CD004916.

 

35. Ong E, Grice K, Held R, Thorn F, Gwiazda J. Effects of spectacle intervention on the progression of myopia in children. Optom Vis Sci. 1999 Jun;76(6):363-9.

 

36. Sankaridurg P, Donovan L, Varnas S, Ho A, Chen X, Martinez A, Fisher S, Lin Z,Smith EL 3rd, Ge J, Holden B. Spectacle lenses designed to reduce progression of myopia: 12-month results. Optom Vis Sci. 2010 Sep;87(9):631-41.

 

37. Norton TT. Animal Models of Myopia: Learning How Vision Controls the Size of the Eye. ILAR J. 1999 Mar;40(2):59-77.

 

38. Wildsoet CF. Active emmetropization--evidence for its existence and

ramifications for clinical practice. Ophthalmic Physiol Opt. 1997 Jul;17(4):279-90.

 

39. Gwiazda J, Thorn F, Bauer J, Held R. Myopic children show insufficient

accommodative response to blur. Invest Ophthalmol Vis Sci. 1993 Mar;34(3):690-4.

 

40. Cheng D, Schmid KL, Woo GC, Drobe B. Randomized trial of effect of bifocal and prismatic bifocal spectacles on myopic progression: two-year results. ArchOphthalmol. 2010 Jan;128(1):12-9.

 

41. Fulk GW, Cyert LA. Can bifocals slow myopia progression? J Am Optom Assoc.1996 Dec;67(12):749-54.

 

42. k GW, Cyert LA, Parker DE. A randomized clinical trial of bifocal glasses

for myopic children with esophoria: results after 54 months. Optometry. 2002

Aug;73(8):470-6.

 

43. Fulk GW, Cyert LA, Parker DE. Baseline characteristics in the Myopia

Progression Study, a clinical trial of bifocals to slow myopia progression. Optom Vis Sci. 1998 Jul;75(7):485-92.

 

44. Pearssinen O, Hemminki E, Klemetti A. Effect of spectacle use and accommodation on myopic progression: Final results of a three year

randomised clinical trial among schoolchildren. Br J Ophthalmol

1989;73:547-51.

 

45. JensenH.Myopia progression in young school children:Aprospective

study ofmyopia progression and the effect of a trial with bifocal lenses

and beta blocker eye drops. Acta Ophthalmol Suppl 1991;200:1-79.

 

46. Fulk GW, Cyert LA, Parker DE. A randomized trial of the effect of single-vision vs. bifocal lenses on myopia progression in children with esophoria. Optom Vis Sci 2000;77:395-401.

 

47.Leung JT, Brown B. Progression of myopia in Hong Kong Chinese School children is slowed by wearing progressive lenses. Optom Vis Sci 1999;76:346–54.

 

48. Edwards MH, Li RW, Lam CS, Lew JK, Yu BS. The Hong Kong

progressive lens myopia control study: study design and main findings.

Invest Ophthalmol Vis Sci 2002;43:2852–8.

 

49.Gwiazda J, Hyman L, Hussein M, Everett D, Norton TT, Kurtz D,Leske MC, Manny R, Marsh-Tootle W, Scheiman M. A randomized clinical trial of progressive addition lenses versus single vision lenses on the progression of myopia in children. Invest Ophthalmol Vis Sci 2003;44:1492–500.

 

50.Hasebe S, Ohtsuki H, Nonaka T, Nakatsuka C, Miyata M, Hamasaki

I, Kimura S. Effect of progressive addition lenses on myopia progression in Japanese children: a prospective, randomized, double-masked, crossover trial. Invest Ophthalmol Vis Sci 2008;49:2781–9.

 

51. Yang Z, Lan W, Ge J, Liu W, Chen X, Chen L, Yu M. The effectiveness of

progressive addition lenses on the progression of myopia in Chinese children.

Ophthalmic Physiol Opt. 2009 Jan;29(1):41-8.

 

52. Shih YF, Hsiao CK, Chen CJ, Chang CW, Hung PT, Lin LL. An intervention trial on efficacy of atropine and multi-focal glasses in controlling myopic progression. Acta Ophthalmol Scand. 2001 Jun;79(3):233-6.

 

53. Correction of Myopia Evaluation Trial 2 Study Group for the Pediatric Eye Disease Investigator Group. Progressive-addition lenses versus single-vision lenses for slowing progression of myopia in children with high accommodative lag and near

esophoria. Invest Ophthalmol Vis Sci 2011; 52: 2749–57.

 

54. Berntsen DA, Sinnott LT, Mutti DO, Zadnik K. A randomized trial using

progressive addition lenses to evaluate theories of myopia progression in

children with a high lag of accommodation. Invest Ophthalmol Vis Sci. 2012 Feb 13;53(2):640-9.

 

55. Jones-Jordan LA, Walline JJ, Mutti DO, Rah MJ, Nichols KK, Nichols JJ, Zadnik K. Gas permeable and soft contact lens wear in children. Optom Vis Sci. 2010 Jun;87(6):414-20.

 

56. Walline JJ, Jones LA, Mutti DO, Zadnik K. A randomized trial of the effects of rigid contact lenses on myopia progression. Arch Ophthalmol. 2004

Dec;122(12):1760-6.

 

57. Walline JJ, Jones LA, Sinnott L, Chitkara M, Coffey B, Jackson JM, Manny RE,Rah MJ, Prinstein MJ; ACHIEVE Study Group. Randomized trial of the effect of contact lens wear on self-perception in children. Optom Vis Sci. 2009 Mar;86(3):222-32.

 

58. Walline JJ, Jones LA, Mutti DO, Zadnik K. Use of a run-in period to decrease loss to follow-up in the Contact Lens and Myopia Progression (CLAMP) study.Control Clin Trials. 2003 Dec;24(6):711-8.

 

59. Walline JJ, Mutti DO, Jones LA, Rah MJ, Nichols KK, Watson R, Zadnik K. The contact lens and myopia progression (CLAMP) study: design and baseline data.Optom Vis Sci. 2001 Apr;78(4):223-33.

 

60. Katz J, Schein OD, Levy B, Cruiscullo T, Saw SM, Rajan U, Chan TK, Yew Khoo C,Chew SJ. A randomized trial of rigid gas permeable contact lenses to reduce progression of children's myopia. Am J Ophthalmol. 2003 Jul;136(1):82-90.

 

61. Aller TA, Wildsoet C. Results of a one-year prospective clinical trial (CONTROL) of the use of bifocal soft contact lenses to control myopia progression. Ophthalmic and Physiological Optics 2006;26(Suppl 1):8–9.

 

62. Cho P, Cheung SW, Edwards M. The longitudinal orthokeratology research in children (LORIC) in Hong Kong: a pilot study on refractive changes and myopic control. Curr Eye Res. 2005 Jan;30(1):71-80.

 

63. Leo SW, Young TL. An evidence-based update on myopia and interventions to retard its progression. J AAPOS. 2011 Apr;15(2):181-9.

 

64. Walline JJ, Jones LA, Sinnott LT. Corneal reshaping and myopia progression. Br J Ophthalmol. 2009 Sep;93(9):1181-5.

 

65. Sankaridurg P, Holden B, Smith E 3rd, Naduvilath T, Chen X, de la Jara PL,Martinez A, Kwan J, Ho A, Frick K, Ge J. Decrease in rate of myopia progression with a contact lens designed to reduce relative peripheral hyperopia: one-year results. Invest Ophthalmol Vis Sci. 2011 Dec ;52(13):9362-7.

 

66. Ganesan P, Wildsoet CF. Pharmaceutical intervention for myopia control. Expert Rev Ophthalmol. 2010 Dec 1;5(6):759-787.

 

67. Yen MY, Liu JH, Kao SC, Shiao CH. Comparison of the effect of atropine and cyclopentolate on myopia. Ann Ophthalmol. 1989 May;21(5):180-2, 187.

 

68. Shih YF, Chen CH, Chou AC, Ho TC, Lin LL, Hung PT. Effects of different

concentrations of atropine on controlling myopia in myopic children. J Ocul

Pharmacol Ther. 1999 Feb;15(1):85-90.

 

69. Romano PE, Donovan JP. Management of progressive school myopia with topical atropine eyedrops and photochromic bifocal spectacles. Binocul Vis Strabismus Q. 2000;15(3):257-60.

 

70. Chiang MF, Kouzis A, Pointer RW, Repka MX. Treatment of childhood myopia with atropine eyedrops and bifocal spectacles. Binocul Vis Strabismus Q 2001;16(3):209-15.

 

71.Chua W, Balakrishnan V, Chan Y. ATOM Study Group. ARVO Analysis of Safety Data for Atropine in the Treatment of Myopia (ATOM) study. Invest. Ophthalmol. Vis. Sci 2002;43 (EAbstract 3329).

 

72. Chua WH, Balakrishnan V, Chan YH, Tong L, Ling Y, Quah BL, Tan D. Atropine for the treatment of childhood myopia. Ophthalmology. 2006 Dec;113(12):2285-91.

 

73. Tong L, Huang XL, Koh AL, Zhang X, Tan DT, Chua WH. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine.Ophthalmology. 2009 Mar;116(3):572-9.

 

74. Bartlett JD, Niemann K, Houde B, Allred T, Edmondson MJ, Crockett RS. A tolerability study of pirenzepine ophthalmic gel in myopic children. J. Ocul. Pharmacol. Ther 2003;19(3):271–279.

 

75. Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, Tan D. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012 Feb;119(2):347-54.

 

76. Lee JJ, Fang PC, Yang IH, Chen CH, Lin PW, Lin SA, Kuo HK, Wu PC. Prevention of myopia progression with 0.05% atropine solution. J Ocul Pharmacol Ther. 2006 Feb;22(1):41-6.

 

77. Chua W-H, Tan D, Balakrishnan V, Chan Y-H. ATOM Study Group. Progression of childhood myopia following cessation of atropine treatment. Invest. Ophthalmol. Vis. Sci 2005;46 Suppl. (EAbstract 4625).

 

78.Yen MY, Liu JH, Kao SC, Shiao CH. Comparison of the effect of atropine and cyclopentolate on myopia. Annals of Ophthalmology 1989;21(5):180-2, 187.

 

79. Stone RA, Lin T, Laties AM. Muscarinic antagonist effects on experimental chick myopia. Exp.Eye Res 1991;52(6):755–758.

 

80.Bartlett JD, Niemann K, Houde B, Allred T, Edmondson MJ, Crockett RS. A tolerability study of pirenzepine ophthalmic gel in myopic children. J. Ocul. Pharmacol. Ther 2003;19(3):271–279.

 

81.Cotter SA, Chu RH, Kwon S. Pirenzepine 2% ophthalmic gel retards myopia progression in 8- to 12-year-old children.Optometry 2003;74:382–3.

 

82. Siatkowski RM, Cotter S, Miller JM, Scher CA, Crockett RS, Novack GD. Safety and efficacy of 2% pirenzepine ophthalmic gel in children with myopia: a 1-year,multicenter, double-masked, placebo-controlled parallel study. Ophthalmology 2004;122(11):1667–74.

 

83. Siatkowski RM, Cotter SA, Crockett RS, Miller JM, Novack GD, Zadnik K; U.S.Pirenzepine Study Group. Two-year multicenter, randomized, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia. J AAPOS. 2008 Aug;12(4):332-9.

 

84. Mitchelson F. Muscarinic receptor agonists and antagonists: effects on ocular

function. Handb Exp Pharmacol. 2012;(208):263-98.

 

85. Tan DT, Lam DS, Chua WH, Shu-Ping DF, Crockett RS; Asian Pirenzepine Study

Group. One-year multicenter, double-masked, placebo-controlled, parallel safety

and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia.

Ophthalmology. 2005 Jan;112(1):84-91.